Skeletal Muscle Aging and Responsiveness in Aged People With MS
Part of paid clinical trials in Oklahoma City, Oklahoma.
- Sponsor
- Oklahoma Medical Research Foundation
- Study ID
- NCT07500727
- Status
- Recruiting
Conditions
- Aging
- Multiple Sclerosis
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Exercise trial consisting of both cardiovascular and strength training — OTHERAll participants will receive 12 weeks of combined ET and RT. All exercise is supervised with a certified trainer. All study staff are CPR trained. Progression of volume and intensity will occur during the ramp-up week and into the first week of training. The ramp-up period increases the number of sets, repetitions, and intensity to limit excessive muscle damage, soreness, and fatigue. Full volume training will be achieved by the end of week one and progression thereafter will be based on intensity. Participants will complete 3x/wk ET and 3x/week RT. Both ET and RT will be progressed on an individual level via monitoring of each session with pragmatic increases in cycling wattage, treadmill speed/grade, and weight lifted as needed. At the completion of training there will be a testing week that repeats the battery of testing completed during the wash-in period to determine responder status by the a priori designated MCIDs for CRF and fMQ.
Study Details
The purposes of this study are to: 1) compare baseline muscle and cardiovascular health in older individuals (\>60 years old) diagnosed with MS to age-matched people without MS, 2) determine muscle and whole body changes to an exercise training program, 3) determine if the muscle in a more affected leg in individuals diagnosed with MS is different from the muscle of a less affected leg, and 4) if or how individuals diagnosed with MS adapt differently than age-matched people without MS to exercise training. Participation in this study will average 1.5 hours per visit, 3 visits per week, for approximately 4 months.
Key Dates
- Start date
- Mar 6, 2026
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: People with MSPeople with MS, 60 or older
Primary Outcome Measure
fMQ [ Time Frame: Week -3 and Week -2 ]
Central Contacts
- Lena Fuentes4052717745
- Bobbette Miller4052714214
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Oklahoma Medical Research Foundation | Oklahoma City | Oklahoma | 73104 |
Find similar trials in Oklahoma City, OK
By condition
By specialty
By research site
Related Studies
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPHASE4 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · New Haven, Connecticut
- The Effect of NAD Supplementation on Brain Vascular Health in AgingPHASE4 · Recruiting · University of Oklahoma · Oklahoma City, Oklahoma
- A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)Recruiting · TG Therapeutics, Inc. · Birmingham, Alabama
- Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)Recruiting · Florida Institute for Human and Machine Cognition · Pensacola, Florida